Areas of Focus
- Drug Design
- Computational Biology
- Molecular Design
Work Experience
- 2014-02~2019-02 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Director, Researcher, Doctoral Supervisor
- 2004-12~2014-02 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher, Doctoral Supervisor, Deputy Director
- 2001-08~2002-02 - Hong Kong University of Science and Technology - Visiting Scholar, Department of Biochemistry
- 1999-07~1999-12 - Weizmann Institute of Science, Israel - Visiting Professor
- 1997-09~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher, Group Leader, Doctoral Supervisor
- 1997-02~1997-07 - Hong Kong University of Science and Technology - Visiting Scholar, Department of Chemistry
- 1995-07~1997-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
- 1987-07~1989-09 - Changzhou Chemical Research Institute, Jiangsu Province - Assistant Researcher
Academic Background & Achievements
- 1992-09--1995-07 PhD in Medicinal Chemistry: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- 1989-09--1992-07 MSc in Physical Chemistry: East China Normal University
- 1983-09--1987-07 BSc in Organic Chemistry: Nanjing University
Publications
- High-Throughput-Methyl-Reading (HTMR) assay: a solution based on nucleotide methyl-binding proteins enables large-scale screening for DNA/RNA methyltransferases and demethylases, 13th Author, 2022
- Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial, 18th Author, 2022
- Structural basis of leukotriene B4 receptor 1 activation, 4th Author, 2022
- A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors, 0th Author, 2022
- Graph neural network approaches for drug-target interactions, 7th Author, 2022
- An inductive graph neural network model for compound-protein interaction prediction based on a homogeneous graph, 7th Author, 2022
- Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody, 22nd Author, 2022
- Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2, 13th Author, 2022
- Computational characterization of transducer recognition of β2 adrenergic receptor, 3rd Author, 2022
- Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations, 9th Author, 2022
- Molecular basis for allosteric agonism and G protein subtype selectivity of galanin receptors, 15th Author, 2022
- Why is the SARS-CoV-2 Omicron variant milder?, 7th Author, 2022
- Structural identification of lysophosphatidylcholines as activating ligands for orphan receptor GPR119, 10th Author, 2022
- Discovery and identification of a novel small molecule BCL-2 inhibitor that binds to the BH4 domain, 11th Author, 2022
- Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1), 12th Author, 2022
- Blood-brain barrier penetration prediction enhanced by uncertainty estimation, 10th Author, 2022
- Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model, 8th Author, 2022
- BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia, 8th Author, 2022
- Drug target inference by mining transcriptional data using a novel graph convolutional network framework, 11th Author, 2022
- Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer, 9th Author, 2022
- Discovery of ARF1-targeting inhibitor demethylzeylasteral as a potential agent against breast cancer, 11th Author, 2022
- Optimizing chemical reaction conditions using deep learning: a case study for the Suzuki-Miyaura cross-coupling reaction, 11th Author, 2020
- Structural basis for activation of the growth hormone-releasing hormone receptor, 17th
Awards
- National Advanced Individual in Fighting COVID-19 (2020): National Level
- Excellent Supervisor Award (2018): Institute Level
- National Class 1.1 New Drug HCl Androxane (2017): Second Prize, National Level
- Shanghai Graduate Excellent Achievement (Thesis) Supervisor Award (2016): City Level
- Shanghai Science and Technology Award (2015): First Prize, Ministry Level
- BHPB Supervisor Research Award (2014): Institute Level
- WuXi AppTec Life Chemistry Award (2010): First Prize, Other
- National Excellent Doctoral Dissertation Supervisor (2010): National Level
- Shanghai Natural Science Peony Award (2009): Ministry Level
- Procter & Gamble Excellent Supervisor Award (2009): Ministry Level
- National Excellent Doctoral Dissertation Supervisor Award (2009): National Level
- CAS Zhu Li Yuehua Excellent Teacher Award (2008): Ministry Level
- National Natural Science Second Prize (2007): Second Prize, National Level
- CAS Excellent Graduate Supervisor Award (2007): Ministry Level
- Ho Leung Ho Lee Foundation Science and Technology Award (2007): Other
- National Excellent Doctoral Dissertation Supervisor Award (2006): National Level
- Shanghai Science and Technology Progress Award (2003): Second Prize, Ministry Level
- 8th Shanghai Science and Technology Elite (2003): Ministry Level
- Shanghai Science and Technology Progress Award (2003): First Prize, Ministry Level
- 5th China Youth Science Award (2002): Ministry Level
- Shanghai New Long March Pioneer (1999): Provincial Level
- Shanghai Science and Technology Progress Award (1999): Third Prize, Ministry Level
- CAS Natural Science Award (1997): Second Prize, Ministry Level
